表紙:抗ウイルス剤の世界市場 - 作用機序別・適応症別・薬物標的の種類別・治療法の種類別・主要地域別:産業動向と将来予測 (2022年~2035年)
市場調査レポート
商品コード
1162458

抗ウイルス剤の世界市場 - 作用機序別・適応症別・薬物標的の種類別・治療法の種類別・主要地域別:産業動向と将来予測 (2022年~2035年)

Antiviral Drugs Market by Mechanism of Action, Target Indication, Type of Drug Target, Type of Therapy and Key Geographies : Industry Trends and Global Forecasts, 2022-2035

出版日: | 発行: Roots Analysis | ページ情報: 英文 194 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.09円
抗ウイルス剤の世界市場 - 作用機序別・適応症別・薬物標的の種類別・治療法の種類別・主要地域別:産業動向と将来予測 (2022年~2035年)
出版日: 2023年07月01日
発行: Roots Analysis
ページ情報: 英文 194 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の抗ウイルス剤市場について分析し、製品の概要や標的疾患、承認済み・治験段階の主な製品、セグメント別・地域別の市場動向の見通し (2022年~2035年)、主な投資・資金調達の動向、事業提携・協力の動き、主な市場促進・抑制要因、主要企業のプロファイルやと製品ポートフォリオ、といった情報を取りまとめてお届けいたします。

目次

第1章 序論

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 抗ウイルス剤の概要
  • ウイルスの種類とウイルス性疾患
  • 抗ウイルス剤の作用機序
  • 抗ウイルス剤の特徴
  • 抗ウイルス剤の利点
  • 抗ウイルス剤の開発に伴う課題
  • 抗ウイルス剤の重要な事実と将来の展望

第4章 市場情勢:承認された抗ウイルス剤

  • 承認された抗ウイルス剤:全体的な市場情勢
  • 承認された抗ウイルス剤:開発企業の情勢

第5章 市場情勢:治験段階の抗ウイルス剤

  • 臨床段階の抗ウイルス剤:全体的な市場情勢
  • 臨床段階の抗ウイルス剤:開発企業の情勢

第6章 企業プロファイル

  • AbbVie
  • AstraZeneca
  • Bristol-Myers Squibb
  • Genentech
  • Gilead Sciences
  • GlaxoSmithKline(GSK)
  • Johnson &Johnson
  • Merck
  • Novartis
  • Pfizer
  • Roche
  • ViiV Healthcare

第7章 事業提携・協力

  • 抗ウイルス剤:事業提携・協力

第8章 資金調達と投資

  • 抗ウイルス剤:資金調達と投資

第9章 ポーターのファイブフォース分析

  • 概要
  • 分析手法と主要指標
  • ポーターのファイブフォース分析

第10章 市場予測と機会分析

  • 予測手法と主な仮定
  • 世界の抗ウイルス剤市場 (2022年~2035年)

第11章 付録1:表形式のデータ

第12章 付録2:企業・組織一覧

図表

LIST OF TABLES

  • Table 4.1 List of Approved Antiviral Drugs
  • Table 4.2 List of Approved Antiviral Drug Developers
  • Table 5.1 List of Clinical-Stage Antiviral Drugs
  • Table 5.2 List of Clinical-Stage Antiviral Drug Developers
  • Table 6.1 AbbVie: Product Portfolio
  • Table 6.2 AbbVie: Recent Developments and Future Outlook
  • Table 6.3 AstraZeneca: Product Portfolio
  • Table 6.4 AstraZeneca: Recent Developments and Future Outlook
  • Table 6.5 Bristol-Myers Squibb: Product Portfolio
  • Table 6.6 Bristol-Myers Squibb: Recent Developments and Future Outlook
  • Table 6.7 Genentech: Product Portfolio
  • Table 6.8 Genentech: Recent Developments and Future Outlook
  • Table 6.9 Gilead Sciences: Product Portfolio
  • Table 6.10 Gilead Sciences: Recent Developments and Future Outlook
  • Table 6.11 GlaxoSmithKline: Product Portfolio
  • Table 6.12 GlaxoSmithKline: Recent Developments and Future Outlook
  • Table 6.13 Johnson & Johnson: Product Portfolio
  • Table 6.14 Johnson & Johnson: Recent Developments and Future Outlook
  • Table 6.15 Merck: Product Portfolio
  • Table 6.16 Merck: Recent Developments and Future Outlook
  • Table 6.17 Novartis: Product Portfolio
  • Table 6.18 Novartis: Recent Developments and Future Outlook
  • Table 6.19 Pfizer: Product Portfolio
  • Table 6.20 Pfizer: Recent Developments and Future Outlook
  • Table 6.21 Roche: Product Portfolio
  • Table 6.22 Roche: Recent Developments and Future Outlook
  • Table 6.23 ViiV Healthcare: Product Portfolio
  • Table 6.24 ViiV Healthcare: Recent Developments and Future Outlook
  • Table 7.1 Antiviral Drugs: List of Partnerships and Collaborations
  • Table 8.1 Antiviral Drugs: List of Funding and Investments
  • Table 12.1 Approved Antiviral Drugs: Distribution by Year of Approval
  • Table 12.2 Approved Antiviral Drugs: Distribution by Type of Dosage Form
  • Table 12.3 Approved Antiviral Drugs: Distribution by Type of Molecule
  • Table 12.4 Approved Antiviral Drugs: Distribution by Type of Target Virus
  • Table 12.5 Approved Antiviral Drugs: Distribution by Route of Administration
  • Table 12.6 Approved Antiviral Drugs: Distribution by Dosing Frequency
  • Table 12.7 Approved Antiviral Drugs: Distribution by Mechanism of Action
  • Table 12.8 Approved Antiviral Drugs: Distribution by Target Indication
  • Table 12.9 Approved Antiviral Drugs Developers: Distribution by Year of Establishment
  • Table 12.10 Approved Antiviral Drugs Developers: Distribution by Company Size
  • Table 12.11 Approved Antiviral Drugs Developers: Distribution by Geography (Region-wise)
  • Table 12.12 Approved Antiviral Drugs Developers: Distribution by Geography (Country-wise)
  • Table 12.13 Most Active Players: Distribution by Number of Approved Drugs
  • Table 12.14 Clinical Antiviral Drugs: Distribution by Phase of Development
  • Table 12.15 Clinical Antiviral Drugs: Distribution by Type of Molecule
  • Table 12.16 Clinical Antiviral Drugs: Distribution by Phase of Development and Type of Molecule
  • Table 12.17 Clinical Antiviral Drugs: Distribution by Type of Dosage Form
  • Table 12.18 Clinical Antiviral Drugs: Distribution by Route of Administration
  • Table 12.19 Clinical Antiviral Drugs: Distribution by Target Indication
  • Table 12.20 Clinical Antiviral Drugs: Distribution by Phase of Development and Target Indication
  • Table 12.21 Clinical Antiviral Drugs: Distribution by Type of Developer
  • Table 12.22 Clinical Antiviral Drugs: Distribution by Type of Therapy
  • Table 12.23 Clinical Antiviral Drugs: Distribution by Target Patient Segment (by Age)
  • Table 12.24 Clinical Antiviral Drugs: Distribution by Mechanism of Action
  • Table 12.25 Clinical Antiviral Drugs: Distribution by Type of Target Virus
  • Table 12.26 Clinical Antiviral Drugs: Distribution by Number of Doses
  • Table 12.27 Clinical Antiviral Drugs Developers: Distribution by Year of Establishment
  • Table 12.28 Clinical Antiviral Drugs Developers: Distribution by Company Size
  • Table 12.29 Clinical Antiviral Drugs Developers: Distribution by Geography (Region-wise)
  • Table 12.30 Clinical Antiviral Drugs Developers: Distribution by Geography (Country-wise)
  • Table 12.31 Clinical Antiviral Drugs Developers: Distribution by Company Size and Location of Headquarters
  • Table 12.32 Most Active Players: Distribution by Number of Clinical-Stage Drugs
  • Table 12.33 Partnerships and Collaborations: Distribution by Year of Partnership
  • Table 12.34 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 12.35 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Table 12.36 Partnerships and Collaborations: Distribution by Target Indication
  • Table 12.37 Partnerships and Collaborations: Distribution by Type of Target Virus
  • Table 12.38 Partnerships and Collaborations: Distribution by Type of Partner
  • Table 12.39 Most Active Players: Distribution by Number of Partnerships
  • Table 12.40 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
  • Table 12.41 Partnerships and Collaborations: International and Local Deals
  • Table 12.42 Funding and Investments: Distribution by Year of Funding
  • Table 12.43 Funding and Investments: Distribution of Amount Invested by Year
  • Table 12.44 Funding and Investments: Distribution of by Type of Fundings
  • Table 12.45 Funding and Investments: Distribution of Amount Invested by Type of Funding
  • Table 12.46 Funding and Investments: Distribution by Target Indication
  • Table 12.47 Funding and Investments: Distribution by Type of Target Virus
  • Table 12.48 Funding and Investments: Distribution by Type of Investor
  • Table 12.49 Most Active Players: Distribution by Number of Instances
  • Table 12.50 Most Active Players: Distribution by Amount Invested
  • Table 12.51 Most Active Investors: Distribution by Number of Instances
  • Table 12.52 Funding and Investments: Distribution of Amount Invested by Region
  • Table 12.53 Funding and Investments: Distribution of Amount Invested by Country
  • Table 12.54 Global Antiviral Drugs Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 12.55 Antiviral Drugs Market: Distribution by Mechanism of Action, 2022 and 2035 (USD Billion)
  • Table 12.56 Antiviral Drugs Market for Fusion Inhibitors, Conservative, Base and Optimistic

Scenarios, 2022-2035 (USD Billion)

  • Table 12.57 Antiviral Drugs Market for DNA Polymerases, Conservative, Base and Optimistic

Scenarios, 2022-2035 (USD Billion)

  • Table 12.58 Antiviral Drugs Market for Protease Inhibitors, Conservative, Base and Optimistic

Scenarios, 2022-2035 (USD Billion)

  • Table 12.59 Antiviral Drugs Market for Reverse Transcriptase Inhibitors, Conservative, Base

and Optimistic Scenarios, 2022-2035 (USD Billion)

  • Table 12.60 Antiviral Drugs Market for Other Mechanisms, Conservative, Base and Optimistic Scenarios,

2022-2035 (USD Billion)

  • Table 12.61 Antiviral Drugs Market: Distribution by Target Indication, 2022 and 2035 (USD Billion)
  • Table 12.62 Antiviral Drugs Market for Human Immunodeficiency virus Infection, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 12.63 Antiviral Drugs Market for Hepatitis Infection, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 12.64 Antiviral Drugs Market for Herpes Simplex Virus Infection, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 12.65 Antiviral Drugs Market for Cytomegalovirus Infection, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 12.66 Antiviral Drugs Market for Influenza Infection, Conservative, Base and Optimistic

Scenarios, 2022-2035 (USD Billion)

  • Table 12.67 Antiviral Drugs Market for Coronavirus Infection, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 12.68 Antiviral Drugs Market for Other Target Indications, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 12.69 Antiviral Drugs Market: Distribution by Drug Target, 2022 and 2035 (USD

Billion)

  • Table 12.70 Antiviral Drugs Market for Virus Targets, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 12.71 Antiviral Drugs Market for Host Targets, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 12.72 Antiviral Drugs Market: Distribution by Type of Therapy, 2022 and 2035 (USD Billion)
  • Table 12.73 Antiviral Drugs Market for Monotherapy, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 12.74 Antiviral Drugs Market for Combination Therapy, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 12.75 Antiviral Drugs Market: Distribution by Geography, 2022 and 2035 (USD Billion)
  • Table 12.76 Antiviral Drugs Market in North America, 2022-2035 (USD Billion)
  • Table 12.77 Antiviral Drugs Market in Europe, 2022-2035 (USD Billion)
  • Table 12.78 Antiviral Drugs Market in Asia-Pacific, 2022-2035 (USD Billion)
  • Table 12.79 Antiviral Drugs Market in Latin America, 2022-2035 (USD Billion)
  • Table 12.80 Antiviral Drugs Market in MENA, 2022-2035 (USD Billion)
  • Table 12.81 Antiviral Drugs Market in Rest of the World, 2022-2035 (USD Billion)

LIST OF FIGURES

  • Figure 2.1 Executive Summary: Overall Market Landscape of Approved Antiviral Drugs
  • Figure 2.2 Executive Summary: Overall Market Landscape of Clinical Antiviral Drugs
  • Figure 2.3 Executive Summary: Partnerships and Collaborations
  • Figure 2.4 Executive Summary: Funding and Investments
  • Figure 2.5 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 3.1 Types of Viruses
  • Figure 3.2 Mechanism of Action of Antiviral Drugs
  • Figure 4.1 Approved Antiviral Drugs: Distribution by Year of Approval
  • Figure 4.2 Approved Antiviral Drugs: Distribution by Type of Dosage Form
  • Figure 4.3 Approved Antiviral Drugs: Distribution by Type of Molecule
  • Figure 4.4 Approved Antiviral Drugs: Distribution by Type of Target Virus
  • Figure 4.5 Approved Antiviral Drugs: Distribution by Route of Administration
  • Figure 4.6 Approved Antiviral Drugs: Distribution by Dosing Frequency
  • Figure 4.7 Approved Antiviral Drugs: Distribution by Mechanism of Action
  • Figure 4.8 Approved Antiviral Drugs: Distribution by Target Indication
  • Figure 4.9 Approved Antiviral Drugs Developers: Distribution by Year of Establishment
  • Figure 4.10 Approved Antiviral Drugs Developers: Distribution by Company Size
  • Figure 4.11 Approved Antiviral Drugs Developers: Distribution by Geography (Region-wise)
  • Figure 4.12 Approved Antiviral Drugs Developers: Distribution by Geography (Country-wise)
  • Figure 4.13 Most Active Players: Distribution by Number of Approved Drugs
  • Figure 5.1 Clinical Antiviral Drugs: Distribution by Phase of Development
  • Figure 5.2 Clinical Antiviral Drugs: Distribution by Type of Molecule
  • Figure 5.3 Clinical Antiviral Drugs: Distribution by Phase of Development and Type of Molecule
  • Figure 5.4 Clinical Antiviral Drugs: Distribution by Type of Dosage Form
  • Figure 5.5 Clinical Antiviral Drugs: Distribution by Route of Administration
  • Figure 5.6 Clinical Antiviral Drugs: Distribution by Target Indication
  • Figure 5.7 Clinical Antiviral Drugs: Distribution by Phase of Development and Target Indication
  • Figure 5.8 Clinical Antiviral Drugs: Distribution by Type of Developer
  • Figure 5.9 Clinical Antiviral Drugs: Distribution by Type of Therapy
  • Figure 5.10 Clinical Antiviral Drugs: Distribution by Target Patient Segment (by Age)
  • Figure 5.11 Clinical Antiviral Drugs: Distribution by Mechanism of Action
  • Figure 5.12 Clinical Antiviral Drugs: Distribution by Type of Target Virus
  • Figure 5.13 Clinical Antiviral Drugs: Distribution by Number of Doses
  • Figure 5.14 Clinical Antiviral Drugs Developers: Distribution by Year of Establishment
  • Figure 5.15 Clinical Antiviral Drugs Developers: Distribution by Company Size
  • Figure 5.16 Clinical Antiviral Drugs Developers: Distribution by Geography (Region-wise)
  • Figure 5.17 Clinical Antiviral Drugs Developers: Distribution by Geography (Country-wise)
  • Figure 5.18 Clinical Antiviral Drugs Developers: Distribution by Company Size and Location of Headquarters
  • Figure 5.19 Most Active Players: Distribution by Number of Clinical-Stage Drugs
  • Figure 7.1 Partnerships and Collaborations: Distribution by Year of Partnership
  • Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 7.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Figure 7.4 Partnerships and Collaborations: Distribution by Target Indication
  • Figure 7.5 Partnerships and Collaborations: Distribution by Type of Target Virus
  • Figure 7.6 Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 7.7 Most Active Players: Distribution by Number of Partnerships
  • Figure 7.8 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
  • Figure 7.9 Partnerships and Collaborations: International and Local Deals
  • Figure 8.1 Funding and Investments: Distribution by Year of Funding
  • Figure 8.2 Funding and Investments: Distribution of Amount Invested by Year
  • Figure 8.3 Funding and Investments: Distribution by Type of Funding
  • Figure 8.4 Funding and Investments: Distribution of Amount Invested by Type of Funding
  • Figure 8.5 Funding and Investments: Distribution by Target Indication
  • Figure 8.6 Funding and Investments: Distribution by Type of Target Virus
  • Figure 8.7 Funding and Investments: Distribution by Type of Investor
  • Figure 8.8 Most Active Players: Distribution by Number of Instances
  • Figure 8.9 Most Active Players: Distribution by Amount Invested
  • Figure 8.10 Most Active Investors: Distribution by Number of Instances
  • Figure 8.11 Funding and Investments: Distribution of Amount Invested by Region
  • Figure 8.12 Funding and Investments: Distribution of Amount Invested by Country
  • Figure 9.1 Antiviral Drugs: Porter's Five Forces Analysis
  • Figure 10.1 Global Antiviral Drugs Market, 2022-2035 (USD Billion)
  • Figure 10.2 Antiviral Drugs Market: Distribution by Mechanism of Action, 2022 and 2035 (USD Billion)
  • Figure 10.3 Antiviral Drugs Market for Fusion Inhibitors, 2022-2035 (USD Billion)
  • Figure 10.4 Antiviral Drugs Market for DNA Polymerases, 2022-2035 (USD Billion)
  • Figure 10.5 Antiviral Drugs Market for Protease Inhibitors, 2022-2035 (USD Billion)
  • Figure 10.6 Antiviral Drugs Market for Reverse Transcriptase Inhibitors, 2022-2035 (USD

Billion)

  • Figure 10.7 Antiviral Drugs Market for Other Mechanisms, 2022-2035 (USD Billion)
  • Figure 10.8 Antiviral Drugs Market: Distribution by Target Indication, 2022 and 2035 (USD Billion)
  • Figure 10.9 Antiviral Drugs Market for Human Immunodeficiency virus Infection, 2022-2035 (USD Billion)
  • Figure 10.10 Antiviral Drugs Market for Hepatitis Infection, 2022-2035 (USD Billion)
  • Figure 10.11 Antiviral Drugs Market for Herpes Simplex Virus Infection, 2022-2035 (USD Billion)
  • Figure 10.12 Antiviral Drugs Market for Cytomegalovirus Infection, 2022-2035 (USD Billion)
  • Figure 10.13 Antiviral Drugs Market for Influenza Infection, 2022-2035 (USD Billion)
  • Figure 10.14 Antiviral Drugs Market for Coronavirus Infection, 2022-2035 (USD Billion)
  • Figure 10.15 Antiviral Drugs Market for Other Target Indications, 2022-2035 (USD Billion)
  • Figure 10.16 Antiviral Drugs Market: Distribution by Drug Target, 2022 and 2035 (USD

Billion)

  • Figure 10.17 Antiviral Drugs Market for Virus Targets, 2022-2035 (USD Billion)
  • Figure 10.18 Antiviral Drugs Market for Host Targets, 2022-2035 (USD Billion)
  • Figure 10.19 Antiviral Drugs Market: Distribution by Type of Therapy, 2022 and 2035 (USD Billion)
  • Figure 10.20 Antiviral Drugs Market for Monotherapy, 2022-2035 (USD Billion)
  • Figure 10.21 Antiviral Drugs Market for Combination Therapy, 2022-2035 (USD Billion)
  • Figure 10.22 Antiviral Drugs Market: Distribution by Geography, 2022 and 2035 (USD Billion)
  • Figure 10.23 Antiviral Drugs Market in North America, 2022-2035 (USD Billion)
  • Figure 10.24 Antiviral Drugs Market in Europe, 2022-2035 (USD Billion)
  • Figure 10.25 Antiviral Drugs Market in Asia-Pacific, 2022-2035 (USD Billion)
  • Figure 10.26 Antiviral Drugs Market in Latin America, 2022-2035 (USD Billion)
  • Figure 10.27 Antiviral Drugs Market in MENA, 2022-2035 (USD Billion)
  • Figure 10.28 Antiviral Drugs Market in Rest of the World, 2022-2035 (USD Billion)
目次
Product Code: RA100384

INTRODUCTION

Infectious diseases are known to be one of the top 10 leading causes of deaths, worldwide. In-fact, more than 40 million people are affected by various types of infectious diseases annually. An article published in The Lancet journal reported that COVID-19 alone caused death of over 18 million people in 2020. , Further, it has been reported that human immunodeficiency virus (HIV) is anticipated to be the cause for 6.5 million deaths globally, by 2030. Over the past few years, a number of antiviral drugs targeting a myriad of infectious diseases, including human immunodeficiency virus (HIV) infection, hepatitis, herpes simplex virus (HSV) infection, cytomegalovirus (CMV) infection, influenza, coronavirus infection (COVID-19) and others, have received approvals from various regulatory authorities, globally. However, it is important to note that, currently, the approved antiviral drugs (around 80) are capable of targeting only 10 of the 220 known viruses that are responsible for causing multiple life threatening infectious diseases in humans. Further, several antiviral drugs are being evaluated across multiple clinical trials for the treatment of various infectious diseases. Moreover, post the onset of the COVID-19 pandemic, extensive research is being conducted to evaluate the safety and efficacy of novel antiviral therapeutics.

The antiviral therapeutic development is fraught with several challenges, including emergence of drug resistance in viruses (as viruses can frequently mutate their genome) and concerns related to drug safety and efficacy. In order to address the aforementioned concerns, several industry stakeholders have been actively leading the R&D efforts for the development of effective antiviral therapeutics against the known viral targets. The COVID-19 pandemic also exposed the lack of effective antiviral therapeutics that can be used for the treatment of re-emerging or emerging viral diseases; this has created opportunities for the development of novel antiviral drugs that can be effective against multiple viruses. Presently, more than 375 companies are engaged in the development of over 420 early and late-stage antiviral drugs, worldwide. These stakeholders have established multiple partnerships and collaborations in order to advance the development of various pipeline candidates. Moreover, in order to fund product development initiatives in this domain, various private and public sector investors have invested around USD 5.5 billion across multiple instances. Driven by the increasing demand for safe and effective antivirals, ongoing pace of innovation in this field, recent partnership activity and sufficient financial support from investors, the antiviral drugs market is anticipated to witness substantial growth in the mid to long-term.

SCOPE OF THE REPORT

The 'Antiviral Drugs Market, 2022-2035: Distribution by Mechanism of Action (Fusion Inhibitors, DNA Polymerases, Protease Inhibitors, Reverse Transcriptase Inhibitors and Others), Target Indication (Human Immunodeficiency virus Infection, Hepatitis, Herpes Simplex Virus Infection, Cytomegalovirus Infection, Influenza, Coronavirus Infection and Others), Type of Drug Target (Virus Targets and Host Targets), Type of Therapy (Monotherapy and Combination Therapy) and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2022-2035' report features an extensive study of the current market landscape and future potential of the antiviral drugs market. The study also includes an in-depth analysis, highlighting the capabilities of antiviral drug developers engaged in this domain. Amongst other elements, the report features:

  • A general overview of the antiviral drugs, along with information on types of viruses and viral diseases, different mechanism of action of antiviral drugs and characteristics and advantages offered by the antiviral drugs. The chapter concludes with a discussion on the challenges associated with the development of antiviral drugs and future prospects in this domain.
  • A detailed assessment of the current market landscape of commercially available antiviral drugs, based on several relevant parameters, such as year of approval, type of dosage form (tablets, capsules, liquids, powders and others /unspecified), type of molecule (small molecules, biologics), type of target virus (DNA virus and RNA virus), route of administration (oral, intravenous, subcutaneous, intramuscular and others / unspecified), dosing frequency, mechanism of action (polymerase inhibition, protease inhibition, reverse transcriptase inhibition, nonnucleoside reverse transcriptase inhibition, integrase strand transfer inhibition, nucleoside reverse transcriptase inhibition, NS5A inhibition, CYP3A inhibition, neuraminidase inhibition, glycoprotein inhibition, immunostimulation, interferon alpha stimulation and viral fusion protein inhibition) and target indication (human immunodeficiency virus infection, hepatitis C infection, hepatitis B infection, herpes simplex virus infection, influenza virus infection, cytomegalovirus infection, coronavirus infection, ebolavirus infection and other indications). In addition, it provides details on the antiviral drug developers, along with analyses based on their year of establishment, company size, geographical location and leading players (in terms of number of approved antiviral drugs).
  • A detailed assessment of the current market landscape of clinical-stage antiviral drugs, based on several relevant parameters, such as phase of development (phase I, phase I/II, phase II, phase II/III and phase III), type of molecule (small molecules, biologics), type of dosage form (tablets, capsules, liquids, powders and others /unspecified), route of administration (oral, intravenous, subcutaneous, intramuscular and others / unspecified), target indication (coronavirus infection, human immunodeficiency virus infection, hepatitis B infection, influenza virus infection, hepatitis C infection, respiratory syncytial virus infection, human papillomavirus infection, herpes simplex virus infection and other indications), type of developer (industry and industry / non-industry), type of therapy (monotherapy and combination therapy), target patient segment, mechanism of action (viral replication inhibition, anti-inflammation, immunostimulants, viral spike protein inhibition, interleukin receptor antagonists, polymerase inhibition, protease inhibition, viral entry inhibition, nucleoside reverse transcriptase inhibition, fusion protein inhibition, capsid protein inhibition, toll-like receptor antagonists, nonnucleoside reverse transcriptase inhibition, tyrosine kinase inhibition, viral core protein inhibition, Janus Kinases inhibition and HIV integrase inhibition), type of target virus (DNA virus and RNA virus) and number of doses. In addition, it provides details on the companies engaged in the development of clinical-stage antiviral drugs, based on their year of establishment, company size, location of headquarters and leading players (in terms of number of clinical-stage drugs).
  • An analysis of partnerships that have been inked by stakeholders engaged in this domain, since 2019, covering instances of clinical trial agreements, R&D agreements, product development and commercialization agreements, manufacturing agreements, product development agreements, commercialization agreements, acquisitions and mergers, product licensing agreements, supply agreements, manufacturing and commercialization agreements, product development and distribution agreements, technology licensing agreements, manufacturing and distribution agreements, distribution agreements and others. Further, the partnership activity in this domain has been analyzed based on several relevant parameters, such as year of partnership, type of partnership, target indication, type of target virus, type of partner, most active players (in terms of number of partnerships) and regional distribution of collaborations.
  • A detailed analysis of investments that have been made into companies engaged in the antiviral drugs domain, since 2019, capturing instances of venture capital financing, capital raised from IPOs and subsequent public offerings, grants, debts and other equity.
  • A qualitative analysis of the five competitive forces, including threats for new entrants, bargaining power of drug developers, bargaining power of buyers, threats of substitute products and rivalry among existing competitors under an insightful Porter's Five Forces framework.
  • Elaborate profiles of prominent players engaged in development of antiviral drugs, featuring a brief overview of the company, details on its product portfolio and recent developments with an informed future outlook.

One of the key objectives of the report was to evaluate the current market size and the future potential associated with the antiviral drugs market, over the coming decades. We have provided informed estimates of the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as mechanism of action (fusion inhibitors, DNA polymerases, protease inhibitors, reverse transcriptase inhibitors and others), target indication (human immunodeficiency virus infection, hepatitis, herpes simplex virus infection, cytomegalovirus infection, influenza, coronavirus infection and others), type of drug target (virus targets and host targets), type of therapy (monotherapy and combination therapy) and key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market's evolution.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in this domain (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

KEY QUESTIONS ANSWERED

  • Who are the key players that have marketed their proprietary antiviral drugs?
  • Who are the leading players currently engaged in the development of clinical-stage antiviral drugs?
  • Which popular disease indications are being targeted by antiviral drugs?
  • What type of partnership models are commonly adopted by industry stakeholders?
  • Who are the key investors supporting research and development related to antiviral drugs?
  • What are the key value drivers that are likely to influence the evolution of the antiviral drugs market?
  • How is the current and future market opportunity, related to antiviral drugs likely to be distributed across key market segments?

CHAPTER OUTLINES

Chapter 2 is an executive summary of the key insights captured during our research. It offers a high-level view on the likely evolution of the antiviral drugs market in the short to mid-term, and long term.

Chapter 3 provides a general overview of the antiviral drugs, along with information on types of viruses and viral diseases. Further, it contains information on different types of mechanism of action of antiviral drugs, and characteristics and advantages offered by the antiviral drugs. The chapter concludes with a discussion on the challenges associated with the development of antiviral drugs and future prospects in this domain.

Chapter 4 includes information on around 80 antiviral drug candidates that are currently approved. The chapter features an elaborate analysis of marketed antiviral drugs based on several relevant parameters, such as such year of approval, type of dosage form (tablets, capsules, liquids, powders and others /unspecified), type of molecule (small molecules, biologics), type of target virus (DNA virus and RNA virus), route of administration (oral, intravenous, subcutaneous, intramuscular and others / unspecified), dosing frequency, mechanism of action (polymerase inhibition, protease inhibition, reverse transcriptase inhibition, nonnucleoside reverse transcriptase inhibition, integrase strand transfer inhibition, nucleoside reverse transcriptase inhibition, NS5A inhibition, CYP3A inhibition, neuraminidase inhibition, glycoprotein inhibition, immunostimulation, interferon alpha stimulation and viral fusion protein inhibition) and target indication (human immunodeficiency virus infection, hepatitis C infection, hepatitis B infection, herpes simplex virus infection, influenza virus infection, cytomegalovirus infection, coronavirus infection, ebolavirus infection and other indications). In addition, it provides details on the companies offering these antiviral drugs, along with analyses based on their year of establishment, company size, geographical location and leading players (in terms of number of approved antiviral drugs).

Chapter 5 includes information of over 420 antiviral drugs that are currently in clinical stages of development. The chapter features an elaborate analysis of clinical-stage antiviral drugs based on several relevant parameters, such as phase of development (phase I, phase I/II, phase II, phase II/III and phase III), type of molecule (small molecules, biologics), type of dosage form (tablets, capsules, liquids, powders and others /unspecified), route of administration (oral, intravenous, subcutaneous, intramuscular and others / unspecified), target indication (coronavirus infection, human immunodeficiency virus infection, hepatitis B infection, influenza virus infection, hepatitis C infection, respiratory syncytial virus infection, human papillomavirus infection, herpes simplex virus infection and other indications), type of developer (industry and industry / non-industry), type of therapy (monotherapy and combination therapy), target patient segment, mechanism of action (viral replication inhibition, anti-inflammation, immunostimulants, viral spike protein inhibition, interleukin receptor antagonists, polymerase inhibition, protease inhibition, viral entry inhibition, nucleoside reverse transcriptase inhibition, fusion protein inhibition, capsid protein inhibition, toll-like receptor antagonists, nonnucleoside reverse transcriptase inhibition, tyrosine kinase inhibition, viral core protein inhibition, Janus Kinases inhibition and HIV integrase inhibition), type of target virus (DNA virus and RNA virus) and number of doses. In addition, it provides details on the companies engaged in the development of clinical-stage antiviral drugs, based on their year of establishment, company size, location of headquarters and leading players (in terms of number of clinical-stage drugs).

Chapter 6 includes brief profiles of prominent players engaged in development of antiviral drugs. Each profile features a brief overview of the company, details related to its product portfolio and recent developments with an informed future outlook.

Chapter 7 provides an elaborate discussion and analysis of the various collaborations and partnerships inked between stakeholders engaged in this domain, since 2019. Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership model (clinical trial agreements, R&D agreements, product development and commercialization agreements, manufacturing agreements, product development agreements, commercialization agreements, acquisitions and mergers, product licensing agreements, supply agreements, manufacturing and commercialization agreements, product development and distribution agreements, technology licensing agreements, manufacturing and distribution agreements, distribution agreements and others), target indication (coronavirus infection, hepatitis B virus infection, human immunodeficiency virus infection, human papillomavirus infection, influenza virus infection and others), type of target virus (DNA virus, RNA virus), type of partner (industry and non-industry), most active player(s) (in terms of number of partnerships inked) and regional distribution (continent and country-wise) of collaborations.

Chapter 8 provides details on the various investments that have been awarded to players engaged in this domain. It includes a detailed analysis of the funding instances that have taken place during the period 2019-2022, highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain.

Chapter 9 provides insights on a qualitative analysis of the five competitive forces, including threats for new entrants, bargaining power of drug developers, bargaining power of buyers, threats of substitute products and rivalry among existing competitors under an insightful Porter's Five Forces framework.

Chapter 10 presents an insightful market forecast analysis, highlighting the likely growth of the antiviral drugs market, for the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across mechanism of action (fusion inhibitors, DNA polymerases, protease inhibitors, reverse transcriptase inhibitors and others), target indication (human immunodeficiency virus infection, hepatitis, herpes simplex virus infection, cytomegalovirus infection, influenza, coronavirus infection and others), type of drug target (virus targets and host targets), type of therapy (monotherapy and combination therapy) and key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world).

Chapter 11 is an appendix, that contains tabulated data and numbers for all the figures included in the report.

Chapter 12 is an appendix, that contains the list of companies and organizations that have been mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Key Questions Answered
  • 1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Overview of Antiviral Drugs
  • 3.2. Types of Viruses and Viral Diseases
  • 3.3. Mechanism of Action of Antiviral Drugs
  • 3.4. Characteristics of Antiviral Drugs
  • 3.5. Advantages of Antiviral Drugs
  • 3.6. Challenges Associated with Development of Antiviral Drugs
  • 3.7. Key Facts and Future Perspectives of Antiviral Drugs

4. MARKET LANDSCAPE: APPROVED ANTIVIRAL DRUGS

  • 4.1. Approved Antiviral Drugs: Overall Market Landscape
    • 4.1.1. Analysis by Year of Approval
    • 4.1.2. Analysis by Type of Dosage Form
    • 4.1.3. Analysis by Type of Molecule
    • 4.1.4. Analysis by Type of Target Virus
    • 4.1.5. Analysis by Route of Administration
    • 4.1.6. Analysis by Dosing Frequency
    • 4.1.7. Analysis by Mechanism of Action
    • 4.1.8. Analysis by Target Indication
  • 4.2. Approved Antiviral Drugs: Developer Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Geography (Region-wise)
    • 4.2.4. Analysis by Geography (Country-wise)
    • 4.2.5. Most Active Players: Analysis by Number of Approved Drugs

5. MARKET LANDSCAPE: CLINICAL ANTIVIRAL DRUGS

  • 5.1. Clinical-Stage Antiviral Drugs: Overall Market Landscape
    • 5.1.1. Analysis by Phase of Development
    • 5.1.2. Analysis by Type of Molecule
    • 5.1.3. Analysis by Phase of Development and Type of Molecule
    • 5.1.4. Analysis by Type of Dosage Form
    • 5.1.5. Analysis by Route of Administration
    • 5.1.6. Analysis by Target Indication
    • 5.1.7. Analysis by Phase of Development and Target Indication
    • 5.1.8. Analysis by Type of Developer
    • 5.1.9. Analysis by Type of Therapy
    • 5.1.10. Analysis by Target Patient Segment (by Age)
    • 5.1.11. Analysis by Mechanism of Action
    • 5.1.12. Analysis by Type of Target Virus
    • 5.1.13. Analysis by Number of Doses
  • 5.2. Clinical-Stage Antiviral Drugs: Developer Landscape
    • 5.2.1. Analysis by Year of Establishment
    • 5.2.2. Analysis by Company Size
    • 5.2.3. Analysis by Geography (Region-wise)
    • 5.2.4. Analysis by Geography (Country-wise)
    • 5.2.5. Analysis by Company Size and Location of Headquarters
    • 5.2.6. Most Active Players: Analysis by Number of Clinical-Stage Drugs

6. COMPANY PROFILES

  • 6.1. AbbVie
    • 6.1.1. Company Overview
    • 6.1.2. Key Executives
    • 6.1.3. Financial Information
    • 6.1.4. Product Portfolio
    • 6.1.5. Recent Developments and Future Outlook
  • 6.2. AstraZeneca
    • 6.2.1. Company Overview
    • 6.2.2. Key Executives
    • 6.2.3. Financial Information
    • 6.2.4. Product Portfolio
    • 6.2.5. Recent Developments and Future Outlook
  • 6.3. Bristol-Myers Squibb
    • 6.3.1. Company Overview
    • 6.3.2. Key Executives
    • 6.3.3. Financial Information
    • 6.3.4. Product Portfolio
    • 6.3.5. Recent Developments and Future Outlook
  • 6.4. Genentech
    • 6.4.1. Company Overview
    • 6.4.2. Key Executives
    • 6.4.3. Product Portfolio
    • 6.4.4. Recent Developments and Future Outlook
  • 6.5. Gilead Sciences
    • 6.5.1. Company Overview
    • 6.5.2. Key Executives
    • 6.5.3. Financial Information
    • 6.5.4. Product Portfolio
    • 6.5.5. Recent Developments and Future Outlook
  • 6.6. GlaxoSmithKline (GSK)
    • 6.6.1. Company Overview
    • 6.6.2. Key Executives
    • 6.6.3. Financial Information
    • 6.6.4. Product Portfolio
    • 6.6.5. Recent Developments and Future Outlook
  • 6.7. Johnson & Johnson
    • 6.7.1. Company Overview
    • 6.7.2. Key Executives
    • 6.7.3. Financial Information
    • 6.7.4. Product Portfolio
    • 6.7.5. Recent Developments and Future Outlook
  • 6.8. Merck
    • 6.8.1. Company Overview
    • 6.8.2. Key Executives
    • 6.8.3. Financial Information
    • 6.8.4. Product Portfolio
    • 6.8.5. Recent Developments and Future Outlook
  • 6.9. Novartis
    • 6.9.1. Company Overview
    • 6.9.2. Key Executives
    • 6.9.3. Financial Information
    • 6.9.4. Product Portfolio
    • 6.9.5. Recent Developments and Future Outlook
  • 6.10. Pfizer
    • 6.10.1. Company Overview
    • 6.10.2. Key Executives
    • 6.10.3. Financial Information
    • 6.10.4. Product Portfolio
    • 6.10.5. Recent Developments and Future Outlook
  • 6.11. Roche
    • 6.11.1. Company Overview
    • 6.11.2. Key Executives
    • 6.11.3. Financial Information
    • 6.11.4. Product Portfolio
    • 6.11.5. Recent Developments and Future Outlook
  • 6.12. ViiV Healthcare
    • 6.12.1. Company Overview
    • 6.12.2. Key Executives
    • 6.12.3. Product Portfolio
    • 6.12.4. Recent Developments and Future Outlook

7. PARTNERSHIPS AND COLLABORATIONS

  • 7.1. Antiviral Drugs: Partnerships and Collaborations
    • 7.1.1. Analysis by Year of Partnership
    • 7.1.2. Analysis by Type of Partnership
    • 7.1.3. Analysis by Year and Type of Partnership
    • 7.1.4. Analysis by Target Indication
    • 7.1.5. Analysis by Type of Target Virus
    • 7.1.6. Analysis by Type of Partner
    • 7.1.7. Most Active Players: Analysis by Number of Partnerships
    • 7.1.8. Geographical Analysis
      • 7.1.8.1. Intercontinental and Intracontinental Deals
      • 7.1.8.2. International and Local Deals

8. FUNDING AND INVESTMENTS

  • 8.1. Antiviral Drugs: Funding and Investments
    • 8.1.1. Analysis by Year of Funding
    • 8.1.2. Analysis of Amount Invested by Year
    • 8.1.3 Analysis by Type of Funding
    • 8.1.4. Analysis of Amount Invested by Type of Funding
    • 8.1.5. Analysis by Target Indication
    • 8.1.6. Analysis by Type of Target Virus
    • 8.1.7. Analysis by Type of Investor
    • 8.1.8. Most Active Players: Analysis by Number of Instances
    • 8.1.9. Most Active Players: Analysis by Amount Invested
    • 8.1.10. Most Active Investors: Analysis by Number of Instances
    • 8.1.11. Geographical Analysis
      • 8.1.11.1. Analysis of Amount Invested by Region
      • 8.1.11.2. Analysis of Amount Invested by Country

9. PORTER'S FIVE FORCES ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Methodology and Key Parameters
  • 9.3. Porter's Five Forces
    • 9.3.1. Threat of New Entrants
    • 9.3.2. Bargaining Power of End Users
    • 9.3.3. Bargaining Power of Drug Developers
    • 9.3.4. Threat of Substitute Products
    • 9.3.5. Rivalry Among Existing Competitors

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 10.1. Forecast Methodology and Key Assumptions
  • 10.2. Global Antiviral Drugs Market, 2022-2035
    • 10.2.1. Antiviral Drugs Market: Distribution by Mechanism of Action, 2022 and 2035
      • 10.2.1.1. Antiviral Drugs Market for Fusion Inhibitors, 2022-2035
      • 10.2.1.2. Antiviral Drugs Market for DNA Polymerases, 2022-2035
      • 10.2.1.3. Antiviral Drugs Market for Protease Inhibitors, 2022-2035
      • 10.2.1.4. Antiviral Drugs Market for Reverse Transcriptase Inhibitors, 2022-2035
      • 10.2.1.5. Antiviral Drugs Market for Other Mechanisms, 2022-2035
    • 10.2.2. Antiviral Drugs Market: Distribution by Target Indication, 2022 and 2035
      • 10.2.2.1. Antiviral Drugs Market for Human Immunodeficiency virus Infection, 2022-2035
      • 10.2.2.2. Antiviral Drugs Market for Hepatitis Infection, 2022-2035
      • 10.2.2.3. Antiviral Drugs Market for Herpes Simplex Virus Infection, 2022-2035
      • 10.2.2.4. Antiviral Drugs Market for Cytomegalovirus Infection, 2022-2035
      • 10.2.2.5. Antiviral Drugs Market for Influenza Infection, 2022-2035
      • 10.2.2.6. Antiviral Drugs Market for Coronaviruses Infection, 2022-2035
      • 10.2.2.7. Antiviral Drugs Market for Other Target Indications, 2022-2035
    • 10.2.3. Antiviral Drugs Market: Distribution by Type of Drug Target, 2022 and 2035
      • 10.2.3.1. Antiviral Drugs Market for Virus Targets, 2022-2035
      • 10.2.3.2. Antiviral Drugs Market for Host Targets, 2022-2035
    • 10.2.4. Antiviral Drugs Market: Distribution by Type of Therapy, 2022 and 2035
      • 10.2.4.1. Antiviral Drugs Market for Monotherapy, 2022-2035
      • 10.2.4.2. Antiviral Drugs Market for Combination Therapy, 2022-2035
    • 10.2.5. Antiviral Drugs Market: Distribution by Geography, 2022 and 2035
      • 10.2.5.1. Antiviral Drugs Market in North America, 2022-2035
      • 10.2.5.2. Antiviral Drugs Market in Europe, 2022-2035
      • 10.2.5.3. Antiviral Drugs Market in Asia-Pacific, 2022-2035
      • 10.2.5.4. Antiviral Drugs Market in Latin America, 2022-2035
      • 10.2.5.5. Antiviral Drugs Market in MENA, 2022-2035
      • 10.2.5.6. Antiviral Drugs Market in Rest of the World, 2022-2035

11. APPENDIX 1: TABULATED DATA

12. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS